WINTON GROUP Ltd Buys Shares of 10,238 Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

WINTON GROUP Ltd bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 10,238 shares of the company’s stock, valued at approximately $265,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Dianthus Therapeutics by 250.0% in the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after purchasing an additional 384,182 shares in the last quarter. Octagon Capital Advisors LP lifted its holdings in Dianthus Therapeutics by 15.4% in the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after purchasing an additional 74,000 shares in the last quarter. Vestal Point Capital LP purchased a new position in Dianthus Therapeutics in the 4th quarter valued at about $1,404,000. Bank of New York Mellon Corp lifted its holdings in Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after purchasing an additional 72,509 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $112,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $26.00 on Thursday. Dianthus Therapeutics, Inc. has a one year low of $6.58 and a one year high of $33.77. The company’s 50 day moving average price is $28.07 and its 200 day moving average price is $26.11. The firm has a market capitalization of $763.07 million, a price-to-earnings ratio of -4.46 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The business had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $0.63 million. Sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on DNTH shares. Cantor Fitzgerald started coverage on shares of Dianthus Therapeutics in a report on Thursday, June 27th. They set an “overweight” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, August 12th. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Robert W. Baird started coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 price objective on the stock. Finally, Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $44.71.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.